評論
打印
In today's podcast, we will discuss a court case involving a leukemia patient from Jiangsu who got him into trouble by buying generic drugs from India via mail order.
在今天的播報中，我們將探討的是一名來自江蘇的白血病病人因通過郵件訂購印度藥品而陷入麻煩的事件。
Lu Yong, a 46-year old exporter from Wuxi, in the eastern province of Jiangsu, will stand trial in a courtin Yuanjiang, in the central province of Hunan, on charges of credit card-related fraud and sales of fake drugs.
46歲的陸勇是一名江蘇無錫的出口商，他將站在湖南沅江法庭的被告席上，理由是他涉嫌利用信用卡銷售造假藥物。
Lu was diagnosed with leukemia more than 10 years ago and was treated with Glivec, a patented drug made byNovartis. The Swiss company got a license to sell the medicine in China in 2002.
陸在10年前被查出患有白血病，并進行了格列衛的治療，這是一個由諾華制藥有限公司出品的專利藥物。這家瑞士公司于2002年拿到了在中國銷售的許可證。
The drug regimen costs 23,500 yuan a month and is not covered by China's health care insurance, meaning itis too expensive for many ordinary people.
使用這種藥物每個月將花費2.35萬元的醫藥費，并不在醫保范疇之列，這就意味著一般家庭來無法負擔高額的醫藥費。
After spending hundreds of thousands of yuan on the medicine, Lu was close to be broke in 2004 when he came across an English-language article mentioning another leukemia drug, Veenat, a much cheaper generic version of Glivec made in India.He bought 3,000 yuan worth of Veenat via mail order, and this helped his condition improve.
花費了十幾萬醫藥費以后，2004年，陸將近破產，就在那時他看到了一篇英文文章，上面介紹了另一種治療白血病的藥物，Veenat，這是一種更為低廉的格列衛藥物，是由印度公司生產的。他通過郵件訂購的方式購買了3000元的藥物，在一個月之內，他的病情有所好轉。
Lu not only switched to the generic drug himself, but also started to help patients he met in an online forum buy it.
路不僅更換了藥物，他還幫助網上論壇中的病人購買藥物。
For this, he was arrested in a crackdown on credit card fraud in Yuanjiang in August 2013. In July, he wascharged with "disrupting management of credit cards" and sales of fake medications.
就因為此案，2013年，他因涉嫌信用卡詐騙而遭到沅江的拘捕。7月，他被指控違反信用卡管理制度，以及銷售假藥。
Luo Jian, a prosecutor in Yuanjiang, told Caixin that any drug lacking a government license – even one made by a registered pharmaceutical company – is classified as a counterfeit under Chinese law.
沅江法官羅建告訴財新網說，任何未經政府許可，就算是注冊的醫藥公司，在中國也被視為造假。
Lu also broke the law by providing his Indian supplier with a credit card he got from abroad，the prosecutor says.
法官說陸還為印度供應商提供了他在國外的信用卡。
The patent for Novartis' Glivec expired in 2013, and at least two China-based pharmaceutical companies have jumped on the opportunity to churn out generic substitutes.
2013年，諾華制藥有限公司的專利到期，之后，至少有2家中國制藥公司搶占先機生產了大量的替代品。
But a generic version produced by Chia Tai Tianqing Pharmaceutical Group in Jiangsu Province cost 4,200 yuan a month and another substitute, from Jiangsu Hansoh Pharmaceutical, cost 3,800 yuan a month. The versions from India cost just 200 yuan a month.
但是，江蘇的正大天晴藥業集團股份有限公司所生產的產品每個月是4200元，江蘇豪森藥業股份有限公司的替代品每個月3800元。而印度的藥物每個月只有200元。
Chinese patients snub locally made generic medicines because they are concerned about quality as well.
中國病人不愿意使用中國藥品，其原因是擔心質量問題。
For Caixin media, this is Philip, Thank you for listening.
這是菲利普為您帶來的財新網報道，感謝收聽。
譯文屬可可英語原創，未經允許，不得轉載。
